Rice Hall James & Associates LLC purchased a new position in shares of Simulations Plus, Inc. (NASDAQ:SLP – Free Report) in the 2nd quarter, Holdings Channel.com reports. The institutional investor purchased 103,010 shares of the technology company’s stock, valued at approximately $1,886,000.
Other large investors also recently added to or reduced their stakes in the company. First Light Asset Management LLC raised its stake in Simulations Plus by 33.7% in the 1st quarter. First Light Asset Management LLC now owns 2,632,823 shares of the technology company’s stock valued at $31,120,000 after acquiring an additional 663,906 shares during the period. Ameriprise Financial Inc. boosted its position in Simulations Plus by 25.3% during the second quarter. Ameriprise Financial Inc. now owns 875,447 shares of the technology company’s stock worth $15,277,000 after purchasing an additional 176,747 shares during the period. Marshall Wace LLP boosted its position in Simulations Plus by 127.5% during the fourth quarter. Marshall Wace LLP now owns 569,783 shares of the technology company’s stock worth $10,387,000 after purchasing an additional 319,301 shares during the period. Stephens Investment Management Group LLC increased its stake in shares of Simulations Plus by 30.8% in the fourth quarter. Stephens Investment Management Group LLC now owns 513,728 shares of the technology company’s stock worth $9,365,000 after purchasing an additional 120,888 shares in the last quarter. Finally, First Eagle Investment Management LLC increased its stake in shares of Simulations Plus by 1,898.1% in the fourth quarter. First Eagle Investment Management LLC now owns 457,155 shares of the technology company’s stock worth $8,334,000 after purchasing an additional 434,275 shares in the last quarter. Hedge funds and other institutional investors own 78.08% of the company’s stock.
Simulations Plus Price Performance
Shares of NASDAQ SLP opened at $18.36 on Wednesday. Simulations Plus, Inc. has a 52 week low of $11.09 and a 52 week high of $21.01. The business has a 50-day simple moving average of $18.12 and a two-hundred day simple moving average of $15.26. The company has a market cap of $371.33 million, a P/E ratio of 45.90 and a beta of 1.32.
Insider Activity at Simulations Plus
In related news, Director Walter S. Woltosz sold 4,177 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $18.44, for a total transaction of $77,023.88. Following the completion of the transaction, the director owned 3,202,131 shares of the company’s stock, valued at approximately $59,047,295.64. The trade was a 0.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 19.10% of the company’s stock.
Wall Street Analyst Weigh In
Several analysts have recently issued reports on SLP shares. Weiss Ratings raised shares of Simulations Plus from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, July 10th. William Blair downgraded shares of Simulations Plus from an “outperform” rating to a “market perform” rating in a report on Wednesday, June 17th. Craig Hallum lowered shares of Simulations Plus from a “buy” rating to a “hold” rating and set a $18.50 price objective for the company. in a research note on Thursday, June 18th. Finally, Wall Street Zen cut shares of Simulations Plus from a “buy” rating to a “hold” rating in a report on Saturday, June 13th. Seven analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Simulations Plus has a consensus rating of “Reduce” and an average price target of $17.25.
Get Our Latest Analysis on Simulations Plus
Simulations Plus Company Profile
Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.
Featured Stories
- Five stocks we like better than Simulations Plus
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Want to see what other hedge funds are holding SLP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Simulations Plus, Inc. (NASDAQ:SLP – Free Report).
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.
